Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that.
Retatrutide phase 2 obesity paper, from the point of view of someone who has read the documentation and is still stuck.
Saying which parts I have understood so that nobody wastes time re-explaining them, and where exactly the understanding stops.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Retatrutide phase 2 in type that I did…
|
+1 | 5 | 31k | 8mo |
|
Why retatrutide discussion here is more cautious than elsewhere — one year on
Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Two things I would like separated before anyone answers on…
|
+92 | 97 | 3.6k | 20h |
|
Retatrutide phase 2 in type 2 diabetes: the Lancet paper
On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. Asking about retatrutide phase 2 in type on behalf of the question I keep seeing…
|
+12 | 16 | 50k | 12mo |
|
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
|
+149 | 159 | 30k | 15mo |
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…
|
+3 | 7 | 1k | 2mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. Collecting what is known about retatrutide phase 2 obesity paper in one place, because…
|
+7 | 11 | 33k | 7mo |
|
A structured critique template this community uses — a second dataset
On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Posting a small dataset on structured critique template. It is mine,…
|
+47 | 51 | 16k | 15h |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…
|
+70 | 76 | 4.8k | 15h |
|
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. The question about measurement error that I actually want answered is the…
|
+117 | 129 | 45k | 5mo |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. Reading SUSTAIN 6 ( N Engl J Med , 2016) for the population rather than the effect,…
|
+110 | 122 | 46k | 1d |